Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.59 |
| ▸ | ITGA4 | P13612 | 20/20 | 0.59 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.59 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443229 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7098071 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7105444 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7098640 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7104171 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7098677 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7100655 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7097651 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7098073 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7102179 | 0.95 | ITGB1 (0.65) | ITGB1ITGA4ITGA2ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6596752-B1 | Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
| US-6482849-B1 | Inhibitors of α4β1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | ITGB1 3/4885ITGA4 8/4885ITGA2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.